biostudies-literatureUnknown40(25)Provencio M<h4>Purpose</h4>Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported.<h4>Methods</h4>This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m² once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 monthJournal of clinical oncology : official journal of the American Society of Clinical Oncology2924-2933https://www.ebi.ac.uk/biostudies/studies/S-EPMC9426809biostudies-literatureOverall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).PMC9426809Majem MMassuti BCasal Rubio JGarcia-Garcia FMartin-Lopez JBernabe Caro RSanchez-Herrero EGarcia-Campelo MRProvencio MLopez Vivanco GCasarrubios MSerna-Blasco RCobo MNadal EDel Barco EDe Castro Carpeno JBarneto Aranda IInsa AMartinez-Marti APereira EViteri SRodriguez-Abreu DRoyuela ARomero ACalvo VFranco FDomine MVinolas NCruz-Bermudez AfalseOverall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).<h4>Purpose</h4>Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported.<h4>Methods</h4>This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m² once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 month2022-01-01T00:00:00Z2022 Sep2025-04-05T11:02:52.629Z2025-02-19T02:49:09.283ZS-EPMC94268093557650810.1200/JCO.21.02660